Aastrom Biosciences to Host Third Quarter 2014 Earnings

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Aastrom Biosciences to Host Third Quarter 2014 Earnings Call on November 13, 2014

ANN ARBOR, Mich., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq: ASTM ), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast:

What: Aastrom Biosciences, Inc., Third Quarter 2014 Earnings Call
When: Thursday, November 13, 2014 at 8:30am (EST)
Where: http://investors.aastrom.com/events.cfm
How:  --- The conference call will be available live in the Investors section of the Aastrom website at http://investors.aastrom.com/events.cfm . Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary.
  --- To participate in the live call by telephone, please call (877) 312-5881 and reference Aastrom Biosciences third quarter 2014 investor conference call. If calling from outside the U.S., please use the international phone number (253) 237-1173.

If you are unable to participate during the live call, the webcast will be available at http://investors.aastrom.com/events.cfm until November 13, 2015. A replay of the call will also be available until 11:59 pm (EST) on November 17, 2014 by calling (855) 859-2056, or from outside the U.S. at (404) 537-3406. The conference ID is 29268567. 

About Aastrom Biosciences

Aastrom Biosciences is the leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. Aastrom markets two autologous cell therapy products in the United States for the treatment of cartilage repair and skin replacement. Aastrom is also developing MACI, a third generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit Aastrom's website at www.aastrom.com .

The Aastrom Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3663   

This document contains forward-looking statements, including, without limitation, statements concerning anticipated progress, objectives and expectations regarding the commercial potential of our products and growth in revenues, intended product development, clinical activity timing, and objectives and expectations regarding the business opportunity described herein, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we intend," and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "potential," "could," "may," or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent risks and uncertainties associated with competitive developments, clinical trial and product development activities, regulatory approval requirements, the availability and allocation of resources among different potential uses, estimating the commercial potential of our products and product candidates and growth in revenues, market demand for our products, and our ability to supply or meet customer demand for our products. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission ("SEC") on March 13, 2014, Quarterly Reports on Form 10-Q and other filings with the SEC. These forward-looking statements reflect management's current views and Aastrom does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.

Media contact: David Salisbury Berry & Company (212) 253-8881 Investor contact: Chad Rubin The Trout Group (646) 378-2947

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Katahdin's Portland Branch Bet Moves Downtown in 2027

Updated Category News Views 61

Exchange Street is getting a real-world vote of confidence, and that is more interesting than another app update ever will be. Katahdin Trust intends to open a full-service branch at 120 Exchange Street in downtown Portland, with renovations slated to begin early in 2027 and an opening expected later that year. For a Maine community bank with nearly $1.2 billion in...

Continue Reading
Washington-to-Asia Advisory Deal Targets Policy Risk

Updated Category News Views 10

Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...

Continue Reading
APEC's Shared-Prosperity Message Needs More Detail

Updated Category News Views 20

Geese make handsome symbols, but markets cannot underwrite a metaphor. The Nov. 18, 2026 report from Xinhua News Agency looks back to remarks Chinese President Xi Jinping made 12 years ago, when he used swan geese to urge APEC economies toward greater cooperation and a new collective flight. Its present-day message is plainly hopeful: the APEC family is moving across the...

Continue Reading
CVRx Lawsuit Deadline Follows a Brutal 59.76% Plunge

Updated Category News Views 24

A 59.76% one-day wipeout has a way of stripping the varnish off every upbeat corporate story. For CVRx investors, the hard fact is that the shares fell $3.55 to close at $2.39 on August 7, 2026, after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That kind of disclosure does not merely dent confidence; it forces...

Continue Reading
Haemonetics Opens Europe for VASCADE MVP XL Device

Updated Category News Views 31

A larger collagen plug is hardly cocktail-party material, yet it can matter a great deal when it sits inside a procedure workflow hospitals are trying to speed up. Haemonetics has received CE Mark certification under the EU Medical Device Regulation for VASCADE MVP XL, its larger-bore venous vascular closure system, and first commercial European procedures were completed...

Continue Reading
Fapon’s Enzyme Push Meets Diagnostics Reality at AMP

Updated Category News Views 85

Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...

Continue Reading
Photocure Opens a New Access Route for Hexvix Patients

Updated Category News Views 31

Forty-plus markets just moved from “not available” toward a workable route for individual bladder cancer patients, and that is the real substance of Photocure’s new arrangement with Clinigen. This is not a sweeping product launch, nor is it an approval announcement dressed up in confetti. It is a Named Patient Program, which matters because the regulatory plumbing...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 68

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 68

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
WYBOT's New Robots Push Hands-Free Pool Care in Lyon

Updated Category News Views 0

A pool robot climbing out of the water to dock itself is the sort of demo that makes people stop mid-aisle at a trade show. WYBOT brought precisely that kind of attention-grabber to Piscine Global Lyon 2026, running November 17–20 at Eurexpo Lyon. The company is showing a broader lineup, but the M3 Pro is plainly the headline act: WYBOT calls it the world's first...

Continue Reading

Top 5 Most Recently Viewed Articles

Michael Baker International Enhances Pavement Management Strategies

Updated Category News Views 313

Michael Baker International Teams Up with CVAG Michael Baker International, a well-known leader in engineering and consulting services, has recently been selected by the Coachella Valley Association of Governments (CVAG) for an important project focused on improving the area's pavement condition assessments. This partnership marks a significant step toward enhancing the...

Continue Reading
Fidus Investment Corporation Announces $100 Million Note Offering

Updated Category News Views 307

Fidus Investment Corporation's Recent Offering Announcement Fidus Investment Corporation (NASDAQ: FDUS) has recently made a significant announcement regarding its financial strategy. The company has priced an underwritten public offering of 6.750% notes, with an aggregate principal amount of $100 million, due in 2030. This initiative is aimed at strengthening its capital...

Continue Reading
WillScot Strengthens Board with New Appointment to Drive Growth

Updated Category News Views 49

WillScot Appoints Worthing Jackman to Board of Directors WillScot Holdings Corporation (NASDAQ: WSC), a leader in flexible space and storage solutions, has made a strategic move by appointing Worthing Jackman to its Board of Directors. This significant addition is aimed at reinforcing the company's growth strategy and bolstering its financial and operational performance....

Continue Reading
National Press Club Reacts to Pentagon's New Media Restrictions

Updated Category News Views 510

Concerns Regarding Pentagon's Media Access Restrictions Recently, the National Press Club leadership voiced significant concerns about new media restrictions imposed by the Pentagon. A statement from the club highlighted that these restrictions threaten transparency and reduce public access to information critical for accountability. Impact on Journalistic Integrity...

Continue Reading
Dogecoin and Shiba Inu Surge: A New Era for Meme Coins

Updated Category News Views 100

A Look at the Recent Surge in Dogecoin and Shiba Inu Recently, Dogecoin and Shiba Inu, both leaders in the meme coin market, have experienced notable price spikes. Dogecoin's value has risen by 4.5%, while Shiba Inu has jumped an impressive 8%. These increases follow important economic news about a cut in interest rates, which is bringing renewed optimism among crypto...

Continue Reading